perhaps if you read the article the podcast was about you would have seen this
“Here comes the answer: Early treatment of people showing first sign and symptoms will result in enhanced rates of recovery from disease and, therefore, raise the number of people who develop life-long protective immunity against the viral variant they got infected with as well as against a diversified spectrum of other, more infectious circulating variants. Enhanced recovery rates will, therefore, contribute to building HI. This particularly applies when a large percentage of the population becomes highly susceptible to Covid-19 disease. Starting multidrug treatment at an early enough stage of the disease may, however, become much more challenging when dealing with ADE. Mass antiviral treatment with whatever drug that effectively reduces viral infectious pressure. This will prevent innate Abs in previously asymptomatically infected individuals from being suppressed by short-lived, S-specific Abs and thus, enable thehealthy, unvaccinated part of thepopulation to deal with all Sars-CoV-2 variants. Such mass antiviral campaigns may need to include pets and live-stock (6) and be combined lockdown rules for as long as titers of theseshort-lived Abs are measurable (i.e., 6-8 weeks). In addition, healthy unvaccinated individuals are likely to contribute to further reducing viral infectious pressureas has recently been observed in the UK shortly after it opened upits society and economy following a period of lockdown rules (7). The higher the fraction of the unvaccinated population, the more ‘more infectious’ immune escape variants face competition from circulating less infectious variants (8) and the more dominant circulation of more infectious variants can be attenuated. As Sars-CoV-2 is notorious for causing high viral shedding in the upper respiratory tract at an early stage of infection and has ahigh proportion of transmission even in pre‐symptomatic and asymptomatic individuals (9), the above measures are unlikely to succeed in sufficiently reducing transmission among healthy individuals. Asymptomatic Sars-CoV-2 transmission may become problematic in that it could resultin regular outbreaks, especially inareas with higher population density (e.g., in cities) or at times where people have close physical contact (e.g., when they live more indoors during winter or at mass gatherings). A durablecontrol of the pandemic will, therefore, ultimately require an immune intervention that is able to prevent infection in all age groups that are naturally susceptible to Covid-19 disease (10) (those are likely to include some age groups < 65 years dueto the high level of innate immune suppression exerted by highly infectious circulating variants). As long as such an immune intervention is not available, antiviral chemoprophylaxis may need to be repeated at regular intervals. However, antiviral chemoprophylaxis should not beconsidered a long-term strategy since overuse of any antiviral compound could potentially promote viral resistance to it. It will, therefore, be critical to closely monitor viral infection rates and restart antiviral chemoprophylaxis as soon as a new surge in cases is about to start.” https://www.geertvandenbossche.org/post/the-last-post
